Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD features prominently at HAI Conference in Miami
AMYPAD features prominently at HAI Conference in Miami 17 Jan 2018 The HAI conference was a great opportunity for presenting AMYPAD. ...
IMI presentation to the European Parliament
IMI presentation to the European Parliament 05 Dec 2017 Alzheimer Europe held a lunch debate in the European Parliament which focused on improving the diagnosis of Alzheimer's disease......
AMYPAD was presented at the Alzheimer Europe Academy
AMYPAD was presented at the Alzheimer Europe Academy 05 Dec 2017 We were glad to see two speakers highlighting the AMYPAD project at the Alzheimer Europe Academy in Brussels......
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.